METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists combine four Immune-Boosting drugs in quest to control tough prostate cancers
Disease control CompletedThis study tested whether combining two, three, or four different immunotherapy drugs could help control advanced prostate cancer that had stopped responding to standard hormone therapy. The trial enrolled 59 adults with this type of cancer or other advanced solid tumors. Researc…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Scientists track cancer Drug's Long-Term risks in major safety study
Disease control CompletedThis study followed over 1,400 men with advanced prostate cancer that had spread to their bones to monitor the long-term safety of the treatment Radium-223. Researchers tracked serious side effects, bone marrow health, and the risk of developing a second, unrelated cancer for up …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Sponsor: Bayer • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
First test of new prostate cancer pill in china
Disease control CompletedThis early-stage study tested a new oral drug called MK-5684 (opevesostat) in 14 Chinese men with advanced prostate cancer that had spread and stopped responding to standard hormone treatments. The main goals were to check the drug's safety, see how well it was tolerated, and mea…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New immune cell therapy tested for Tough-to-Treat prostate cancer
Disease control CompletedThis early-stage study tested a new cell therapy called INKmune in men with advanced prostate cancer that had spread and stopped responding to standard hormone treatments. The main goals were to find the safest and most effective dose and to see how well patients tolerated the tr…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New pill offers hope for men with Tough-to-Treat prostate cancer
Disease control CompletedThis study tested a new approach for men whose prostate cancer has spread and stopped responding to standard hormone-blocking treatments. Researchers gave participants a high-dose oral testosterone pill in a one-week-on, one-week-off cycle for three months to see if it could shri…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC
-
Targeted therapy tested for tough prostate cancer cases
Disease control CompletedThis study tested whether a targeted drug called olaparib works better than standard hormone treatments for Chinese men with advanced prostate cancer that has spread and stopped responding to other hormone therapies. The men in the study all had specific genetic changes (BRCA1/2 …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 02, 2026 15:24 UTC
-
New scan seeks to outperform old methods in tracking deadly prostate cancer
Knowledge-focused CompletedThis small pilot study tested whether a newer type of PET scan (using a tracer called 18F-fluciclovine) could better track how well treatments are working for men with advanced, hard-to-treat prostate cancer that has spread. Researchers compared the new scan results to standard C…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Tulane University • Aim: Knowledge-focused
Last updated Mar 17, 2026 13:09 UTC